publications

publications by categories in reversed chronological order. generated by jekyll-scholar.

2025

  1. Longitudinal profiling of tumor and immune compartments uncovers patterns of dysregulation and associations with response in multiple myeloma
    D. J. Ohlstrom, W. C. Pilcher, M. E. Michaud, and 33 more authors
    Blood Cancer Discovery, 2025
    DOI
  2. Long-term remission after Cilta-Cel in multiple myeloma is linked to diverse T cells and low myeloid suppression
    J. Santos, D. T. Melnekoff, A. Aleman, and 26 more authors
    Blood Advances, 2025
    In press
  3. A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma
    W. C. Pilcher, L. Yao, E. Gonzalez-Kozlova, and 58 more authors
    Nature Cancer, 2025
    In press
  4. Targeted therapy of CAR+ T-cell lymphoma after anti-BCMA CAR T-cell therapy
    A. Aleman, O. Van Oekelen, D. Melnekoff, and 32 more authors
    New England Journal of Medicine, 2025
    DOI

2024

  1. The genetic and molecular drivers of multiple myeloma: current insights, clinical implications, and the path forward
    M. Ram, M. R. Fraser, J. Santos, and 5 more authors
    Pharmacogenomics and Personalized Medicine, 2024
    DOI
  2. Predictors of response to venetoclax and therapeutic potential of CDK7 inhibition in multiple myeloma
    R. P. Dutta, S. Thibaud, V. Leshchenko, and 21 more authors
    Blood Neoplasia, 2024
    DOI
  3. FaMMily Affairs: dissecting inherited contributions to multiple myeloma risk
    S. Bodnar, T. Brander, J. Gold, and 6 more authors
    Seminars in Hematology, 2024
    DOI
  4. Melanoma antigen genes (MAGE): novel functional targets in multiple myeloma
    A. H. Mei, Alessandro Laganà, R. Osman, and 1 more author
    Seminars in Hematology, 2024
    DOI
  5. The role of 1q abnormalities in multiple myeloma: genomic insights, clinical implications, and therapeutic challenges
    Z. M. Avigan, C. S. Mitsiades, and Alessandro Laganà
    Seminars in Hematology, 2024
    DOI
  6. Multiple myeloma risk and outcomes are associated with pathogenic germline variants in DNA repair genes
    S. Thibaud, R. L. Subaran, S. Newman, and 21 more authors
    Blood Cancer Discovery, 2024
    DOI
  7. Iberdomide increases innate and adaptive immune cell subsets in the bone marrow of patients with relapsed/refractory multiple myeloma
    O. Van Oekelen, M. Amatangelo, M. Guo, and 14 more authors
    Cell Reports Medicine, 2024
    DOI

2023

  1. Sequencing T-cell redirection therapies leads to deep and durable responses in relapsed/refractory myeloma patients
    T. H. Mouhieddine, O. Van Oekelen, D. T. Melnekoff, and 19 more authors
    Blood Advances, 2023
    DOI

2022

  1. Pan-cancer analysis of canonical and modified miRNAs enhances the resolution of the functional miRNAome in cancer
    R. Distefano, L. Tomasello, G. L. Rampioni Vinciguerra, and 10 more authors
    Cancer Research, 2022
  2. Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation
    M. Elnaggar, S. Agte, P. Restrepo, and 11 more authors
    Journal of Hematology & Oncology, 2022
    DOI
  3. A three-gene signature predicts response to selinexor in multiple myeloma
    P. Restrepo, S. Bhalla, Y. Ghodke-Puranik, and 15 more authors
    JCO Precision Oncology, 2022
    DOI

2021

  1. Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy
    O. Van Oekelen, A. Aleman, B. Upadhyaya, and 14 more authors
    Nature Medicine, 2021
    DOI
  2. Patient similarity network of multiple myeloma identifies patient sub-groups with distinct genetic and clinical features
    S. Bhalla, D. T. Melnekoff, A. Aleman, and 14 more authors
    Science Advances, 2021
    DOI
  3. SOX11 inhibitors are cytotoxic in mantle cell lymphoma
    S. S. Jatiani, S. Christie, V. V. Leshchenko, and 15 more authors
    Clinical Cancer Research, 2021
    DOI
  4. MiREDiBase, a manually curated database of validated and putative editing events in microRNAs
    G. P. Marceca, R. Distefano, L. Tomasello, and 11 more authors
    Scientific Data, 2021
    DOI
  5. Optimal supportive care with selinexor improves outcomes in patients with relapsed/refractory multiple myeloma
    A. Chari, E. Florendo, I. S. Mancia, and 10 more authors
    Clinical Lymphoma, Myeloma & Leukemia, 2021
    DOI

2020

  1. A critical role for fas-mediated off-target tumor killing in T cell immunotherapy
    R. Upadhyay, J. A. Boiarsky, G. Pantsulaia, and 14 more authors
    Cancer Discovery, 2020
    DOI
  2. MicroRNA profiling of blastic plasmacytoid dendritic cell neoplasm and myeloid sarcoma
    M. R. Sapienza, F. Fuligni, F. Melle, and 16 more authors
    Hematological Oncology, 2020
    DOI
  3. A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myeloma
    O. Van Oekelen, S. Parekh, H. J. Cho, and 23 more authors
    Leukemia & Lymphoma, 2020
    DOI
  4. Discovery of a first-in-class EZH2 selective degrader
    A. Ma, E. Stratikopoulos, K. S. Park, and 12 more authors
    Nature Chemical Biology, 2020
    DOI
  5. Patient-specific mutation-derived tumor antigens as targets for cancer immunotherapy in multiple myeloma
    D. Perumal, N. Imai, Alessandro Laganà, and 15 more authors
    Clinical Cancer Research, 2020
    DOI

2019

  1. A network analysis of multiple myeloma related gene signatures
    Y. Liu, H. Yu, S. Yoo, and 6 more authors
    Cancers, 2019
    DOI

2018

  1. Precision medicine for relapsed multiple myeloma on the basis of an integrative multiomics approach
    Alessandro Laganà, I. Beno, D. Melnekoff, and 16 more authors
    JCO Precision Oncology, 2018
    DOI
  2. KRAS induces lung tumorigenesis through microRNAs modulation
    L. Shi, J. Middleton, Y. J. Jeon, and 10 more authors
    Cell Death & Disease, 2018
    DOI

2017

  1. PDGFR-modulated miR-23b cluster and miR-125a-5p suppress lung tumorigenesis by targeting multiple components of KRAS and NF-kB pathways
    S. Naidu, L. Shi, P. Magee, and 10 more authors
    Scientific Reports, 2017
    DOI
  2. miRandola 2017: a curated knowledge base of non-invasive biomarkers
    F. Russo, S. Di Bella, F. Vannini, and 16 more authors
    Nucleic Acids Research, 2017
    DOI
  3. A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myeloma
    A. Chari, H. J. Cho, A. Dhadwal, and 16 more authors
    Blood Advances, 2017
    DOI
  4. Discovery and characterization of the feline miRNAome
    Alessandro Laganà, W. P. Dirksen, W. Supsavhad, and 6 more authors
    Scientific Reports, 2017
    DOI
  5. Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma
    Alessandro Laganà, D. Perumal, D. Melnekoff, and 15 more authors
    Leukemia, 2017
    DOI
  6. Selective targeting of point-mutated KRAS through artificial microRNAs
    M. Acunzo, G. Romano, G. Nigita, and 9 more authors
    Proceedings of the National Academy of Sciences of the United States of America, 2017
    DOI

2016

  1. Non-coding RNA: current deep sequencing data analysis approaches and challenges
    D. Veneziano, S. Di Bella, G. Nigita, and 3 more authors
    Human Mutation, 2016
  2. miR-579-3p controls melanoma progression and resistance to target therapy
    L. Fattore, R. Mancini, M. Acunzo, and 13 more authors
    Proceedings of the National Academy of Sciences of the United States of America, 2016
    DOI
  3. microRNA editing in seed region aligns with cellular changes in hypoxic conditions
    G. Nigita, M. Acunzo, G. Romano, and 6 more authors
    Nucleic Acids Research, 2016
    DOI

2015

  1. Identification of general and heart-specific miRNAs in sheep (Ovis aries)
    Alessandro Laganà, D. Veneziano, T. Spata, and 4 more authors
    PLOS ONE, 2015
    DOI
  2. Editorial: Bioinformatics of non-coding RNAs with applications to biomedicine: recent advances and open challenges
    Alessandro Laganà, A. Ferro, and C. M. Croce
    Frontiers in Bioengineering and Biotechnology, 2015
    DOI
  3. Quaking and miR-155 interactions in inflammation and leukemogenesis
    E. Tili, M. Chiabai, D. Palmieri, and 15 more authors
    Oncotarget, 2015
  4. MicroRNA-148a reduces tumorigenesis and increases TRAIL-induced apoptosis in NSCLC
    P. Joshi, Y. J. Jeon, Alessandro Laganà, and 4 more authors
    Proceedings of the National Academy of Sciences of the United States of America, 2015
  5. A set of NF-kB-regulated microRNAs induces acquired TRAIL resistance in lung cancer
    Y. J. Jeon, J. Middleton, T. Kim, and 15 more authors
    Proceedings of the National Academy of Sciences of the United States of America, 2015
  6. A differentially expressed set of microRNAs in cerebro-spinal fluid (CSF) can diagnose CNS malignancies
    A. Drusco, A. Bottoni, Alessandro Laganà, and 15 more authors
    Oncotarget, 2015
  7. MicroRNAs and targeted therapies in non-small cell lung cancer: minireview
    C. Tibaldi, A. D’Incecco, and Alessandro Laganà
    Anti-Cancer Agents in Medicinal Chemistry, 2015

2014

  1. Synthetic RNAs for gene regulation: design principles and computational tools
    Alessandro Laganà, D. Shasha, and C. M. Croce
    Frontiers in Bioengineering and Biotechnology, 2014
    DOI
  2. Imprint cytopathology of core needle biopsies: a first responder role for cytotechnologists
    S. V. Thomas, Alessandro Laganà, K. M. Dittmar, and 1 more author
    Journal of the American Society of Cytopathology, 2014
  3. Human HMGA2 protein overexpressed in mice induces precursor T-cell lymphoblastic leukemia
    A. Efanov, N. Zanesi, V. Coppola, and 7 more authors
    Blood Cancer Journal, 2014
  4. A knowledge base for the discovery of function, diagnostic potential and drug effects on cellular and extracellular miRNAs
    F. Russo, S. Di Bella, V. Bonnici, and 6 more authors
    BMC Genomics, 2014
    Supplement 3: S4
  5. miR-Synth: a computational resource for the design of multi-site multi-target synthetic miRNAs
    Alessandro Laganà, M. Acunzo, G. Romano, and 8 more authors
    Nucleic Acids Research, 2014
    DOI

2013

  1. Neuropilin-2 is upregulated in lung cancer cells during TGF\ensuremathβ1-induced epithelial-mesenchymal transition
    P. Nasarre, R. M. Gemmill, V. A. Potiron, and 8 more authors
    Cancer Research, 2013
  2. Extracellular circulating viral microRNAs: current knowledge and perspectives
    Alessandro Laganà, F. Russo, D. Veneziano, and 5 more authors
    Frontiers in Genetics, 2013
  3. Cross-talk between MET and EGFR in non-small cell lung cancer involves miR-27a and Sprouty2
    M. Acunzo, G. Romano, D. Palmieri, and 7 more authors
    Proceedings of the National Academy of Sciences of the United States of America, 2013
  4. In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation
    F. Pichiorri, D. Palmieri, L. De Luca, and 19 more authors
    Journal of Experimental Medicine, 2013
  5. A Sleeping Beauty screen reveals NF-kB activation in CLL mouse model
    N. Zanesi, V. Balatti, J. Riordan, and 8 more authors
    Blood, 2013
  6. cMyc/miR-125b-5p signalling determines sensitivity to bortezomib in preclinical model of cutaneous T-cell lymphomas
    V. Manfè, E. Biskup, A. Willumsgaard, and 8 more authors
    PLOS ONE, 2013
  7. VIRGO: visualization of A-to-I RNA editing sites in genomic sequences
    R. Distefano, G. Nigita, V. Macca, and 4 more authors
    BMC Bioinformatics, 2013
    Supplement 7: S5

2012

  1. miRandola: extracellular circulating microRNAs database
    F. Russo, S. Di Bella, G. Nigita, and 5 more authors
    PLOS ONE, 2012
  2. miR-EdiTar: a database of predicted A-to-I edited miRNA target sites
    Alessandro Laganà, A. Paone, D. Veneziano, and 11 more authors
    Bioinformatics, 2012
  3. Regulation of acute graft-versus-host disease by microRNA-155
    P. Ranganathan, C. E. Heaphy, S. Costinean, and 24 more authors
    Blood, 2012

2010

  1. Variability in the incidence of miRNAs and genes in fragile sites and the role of repeats and CpG islands in the distribution of genetic material
    Alessandro Laganà, F. Russo, C. Sismeiro, and 3 more authors
    PLOS ONE, 2010
  2. Prediction of human targets for viral-encoded microRNAs by thermodynamics and empirical constraints
    Alessandro Laganà, S. Forte, F. Russo, and 3 more authors
    Journal of RNAi and Gene Silencing, 2010

2009

  1. miRò: a miRNA knowledge base
    Alessandro Laganà, S. Forte, A. Giudice, and 6 more authors
    Database, 2009
  2. The treatment with the fusion inhibitor enfuvirtide influences the appearance of mutations in the HIV-1 regulatory protein Rev
    V. Svicher, C. Alteri, R. D’Arrigo, and 17 more authors
    Antimicrobial Agents and Chemotherapy, 2009

2008

  1. Involvement of GTA protein NC2beta in neuroblastoma pathogenesis suggests that it physiologically participates in the regulation of cell proliferation
    C. Di Pietro, M. Ragusa, D. Barbagallo, and 22 more authors
    Molecular Cancer, 2008

2007

  1. Genomics, evolution and expression of TBPL2, a member of the TBP family
    C. Di Pietro, M. Ragusa, L. Duro, and 20 more authors
    DNA and Cell Biology, 2007